Announcement on the wholly-owned subsidiary obtaining a notice of approval for the marketing application of chemical raw materials
Meeting materials of the 2024 First Extraordinary General Meeting of Shareholders
Notice on Obtaining a Notice of Approval for Drug Supplementation Applications
Notice on the holding subsidiary receiving a notice of approval for the drug supplement application
Notice on wholly-owned subsidiaries obtaining drug registration certificates
Announcement on the holding subsidiary obtaining a notice of approval for the marketing application of chemical raw materials
Notice on holding the 2024 First Extraordinary General Meeting of Shareholders
2024 “Improve Quality, Increase Efficiency, and Focus on Return” Action Plan
Report on the 2024 semi-annual risk continuity assessment of Sinopharm Group Finance Co., Ltd.
Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs
Announcement Regarding Holding Subsidiary Pharmaceutical Passed Generic Drug Consistency Evaluation
Announcement regarding the subsidiary obtaining the pharmaceutical supplementary application approval letter.
Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs
Announcement regarding the resignation of senior management personnel.
Announcement regarding the subsidiary obtaining the pharmaceutical supplementary application approval letter.
Announcement on Obtaining Approval Notice for Supplementary Application of Pharmaceutical
Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs
Announcement on the Progress of the Pharmaceutical Marketing Authorization Transfer Contract.
Announcement regarding the holding subsidiary's acquisition of pharmaceutical registration certificate.
Announcement regarding obtaining overseas marketing authorization for injectable cefuroxime sodium.
No Data